Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting

Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the effica...

Full description

Bibliographic Details
Main Authors: Debmalya Sanyal, Anirban Majumdar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=7;spage=301;epage=303;aulast=Sanyal